References
- Bick RL. Preface. Semin Thromb Hemost 1999; 25(3): 251–3
- Laffan M, Tuddenham E. Science, medicine, and the future: assessing thrombotic risk. BMJ 1998; 317(7157): 520–3
- Lensing AW, Prandoni P, Prins MH, et al. Deep-vein thrombosis. Lancet 1999; 353(9151): 479–85
- Bick RL, Kaplan H. Syndromes of thrombosis and hypercoagulability: congenital and acquired causes of thrombosis. Med Clin North Am 1998; 82(3):409–58
- Bauer KA, Goodnight SH, Ridker PM. Hypercoagulable states—translation of risk factors to clinical practice. American Society of Hematology education session, Dec 1998; 255–73
- Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353(9159): 1167–73
- Bauer KA. The hypercoagulable state: evaluation and management. Update on thrombophilia. American Society of Hematology education session, 1999; 231–5
- van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 1998; 12(6): 1141–66
- Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993; 119(8): 819–27
- Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg 506→Gin mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336(6): 399–403
- Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127(10): 895–903
- De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341(11):801–6
- Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342(6): 374–80
- Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338(15): 1042–50
- Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332(15): 993–7
- Prandoni P, Lensing AW, Biiller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327(16): 1128–33
- Cornuz J, Pearson SD, Creager MA, et al. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125(10): 785–93
- Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336(6): 393–8
- Diuguid DL. Oral anticoagulant therapy for venous thromboembolism. N Engl J Med 1997; 336(6): 433–4
- Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340(12): 901–7
- Schafer AI. Venous thrombosis as a chronic disease. N Engl J Med 1999; 340(12): 955–6
- Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86(10): 3685–91